16:35 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Acceleron's ACE-083 increases muscle volume in Phase II for Charcot-Marie-Tooth disease

Acceleron Pharma Inc. (NASDAQ:XLRN) reported preliminary data from 18 patients with Charcot-Marie-Tooth disease in Part 1 of a Phase II trial showing that ACE-083 increased mean total muscle volume by 12.6-14.2%, increased mean contractile muscle...
19:24 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

Acceleron reports preliminary Phase II data for ACE-083 in FSHD

Acceleron Pharma Inc. (NASDAQ:XLRN) reported preliminary data from Part 1 of a Phase II trial evaluating ACE-083 to treat facioscapulohumeral muscular dystrophy (FSHD). The company expects to start Part 2 of the trial next quarter...
21:26 , Sep 29, 2017 |  BC Week In Review  |  Clinical News

Acceleron starts Phase II trial of ACE-083 to treat Charcot-Marie-Tooth disease

Acceleron Pharma Inc. (NASDAQ:XLRN) began a Phase II trial of ACE-083 to treat Charcot-Marie-Tooth disease. The trial’s primary endpoints are safety for the first part and change from baseline in muscle volume for the second...
23:41 , Jun 12, 2017 |  BC Extra  |  Clinical News

Acceleron's dalantercept fails in Phase II RCC trial

Acceleron Pharma Inc. (NASDAQ:XLRN) said it is discontinuing development of dalantercept ( ACE-041 ) after the candidate missed the primary endpoint in the Phase II DART study to treat advanced renal cell carcinoma. Among 119...
00:41 , Jan 12, 2017 |  BC Week In Review  |  Clinical News

ACE-083: Ph II started

Acceleron began a U.S. Phase II trial to evaluate 150, 200 and 250 mg intramuscular ACE-083 given 3 weeks apart for up to 5 doses in patients with muscle weakness in the bicep or tibialis...
01:32 , Jan 7, 2016 |  BC Extra  |  Financial News

Acceleron raises $150M in follow-on

Acceleron Pharma Inc. (NASDAQ:XLRN) raised $150 million through the sale of 3.8 million shares at $40 in a follow-on underwritten by Morgan Stanley, Leerink, UBS, JMP Securities and FBR. The company proposed the offering Monday...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Clinical News

ACE-083: Preliminary Phase I data

Preliminary data from a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 40 healthy postmenopausal female volunteers showed that single intramuscular injections of 50, 100 and 200 mg ACE-083 and 2 injections of 100, 150...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

Acceleron Pharma Inc preclinical data

In mice, twice-weekly 100 ug ACE-083 injected into the right tibialis anterior muscle for 3 weeks increased muscle mass by 73% in the injected muscle vs. vehicle-treated controls (p<=0.0001). The increase in mass was associated...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Clinical News

ACE-083: Phase I started

Acceleron began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate single intramuscular injections of 50, 100 and 200 mg ACE-083 and 2 doses of 100 and 200 mg ACE-083 given 3 weeks apart...